Sp753

NOD2 MEDIATES LGR5+INTESTINAL STEM CELL PROTECTION AGAINST ROS CYTOTOXICITY

Date
May 8, 2023
Explore related products in the following collection:

Society: AGA

Reactive oxygen species (ROS) are by-products of normal cellular metabolism with low to moderate amounts being beneficial in several physiological processes in the intestine. Chemotherapy and radiotherapies are largely based upon ROS generation to destroy malignant cells by inducing apoptosis. Nonetheless, disproportionate generation of ROS causes oxidative tissue damage and development of a range of gut disorders including inflammatory bowel diseases. Considering the role of oxidative stress in IBD, implementation of antioxidant therapy such as 5-aminosalicylic acid has been commonly used in patients. However, given the challenges in antioxidant therapies in IBD including effectiveness and interference with normal redox signaling, there is a dire need to develop efficient and targeted therapies. Thus, there has been a growing interest in understanding the metabolic precursors of ROS, their effects on host intestinal epithelium as well as implications in diseases including intestinal inflammation. This basic and translational symposium aims to bring together various aspects of redox signaling ranging from role of ROS in modulating intestinal barrier function, role of mitochondria and ER in epithelial cell lineages and discussing the role of microbiota in intestinal oxidative stress. In addition, the experts in the field will be discussing the mechanisms pertinent to protect intestinal epithelium from oxidative insult and illuminate the current landscape and prospectives on redox targeted therapeutics for GI diseases.

Tracks

Related Products

Thumbnail for MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for PLACEHOLDER
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
Thumbnail for ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
ACTIVATING TRANSCRIPTION FACTOR 6 ACCELERATES MICROBIOTA-DEPENDENT RISK FOR COLITIS-ASSOCIATED CANCER IN INFLAMMATORY BOWEL DISEASES
BACKGROUND AND AIMS: Chemoresistance is a major cause of colorectal cancer (CRC) recurrence and death. The critical role of gut microbiome in the efficacy of CRC chemotherapy remains unclear…
Thumbnail for INTRODUCTION
INTRODUCTION
SOCIETY: AGA